RT Journal Article
SR Electronic
T1 Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.01.22271735
DO 10.1101/2022.03.01.22271735
A1 Kanokudom, Sitthichai
A1 Assawakosri, Suvichada
A1 Suntronwong, Nungruthai
A1 Chansaenroj, Jira
A1 Auphimai, Chompoonut
A1 Nilyanimit, Pornjarim
A1 Vichaiwattana, Preeyaporn
A1 Thongmee, Thanunrat
A1 Yorsaeng, Ritthideach
A1 Duangchinda, Thaneeya
A1 Chantima, Warangkana
A1 Pakchotanon, Pattarakul
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Klinfueng, Sirapa
A1 Mongkolsapaya, Juthathip
A1 Sudhinaraset, Natthinee
A1 Wanlapakorn, Nasamon
A1 Honsawek, Sittisak
A1 Poovorawan, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/03/02/2022.03.01.22271735.abstract
AB The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The present study compared the reactogenicity and immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results showed that headache, joint pain, and diarrhea were more frequent in the 15 μg-than the 30 μg-BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 μg-than the 50 μg-mRNA-1273 groups. No significant differences in immunogenicity were detected. These findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose. The reduced dose could be used to increase vaccine coverage in situations of limited global vaccine supply.HighlightsThe 15 μg- and 30 μg-BNT162b2, and 50 μg- and 100 μg-mRNA-1273 booster doses were comparedBooster vaccination with the mRNA vaccine elicits high Ig and IgG anti-RBD in CoronaVac-vaccinated adultsNo differences were observed in antibody responses after the reduced or standard booster dose of the mRNA vaccine in CoronaVac-vaccinated adultsNeutralizing antibodies against the delta and omicron variants were significantly higher after the booster doseNeutralizing antibody titers were lower against the omicron variant than the delta variant in all vaccinated adultsCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialThis trial was included on the Thai Clinical Trials Registry (TCTR 20210910002).Funding StatementThis research was financially supported by Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially supported by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB number 690/64).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.